Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Humana Inc (HUM) Price & Performance

Hinge Health Inc. Class A Common StockTrade
Humana IncTrade

Price performance (Past 24H)

Key statistics

Hinge Health Inc. Class A Common Stock vs Humana Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Humana Inc trades at $427.5 (market cap $50.48B). The key difference: Humana Inc is far larger — about 6× Hinge Health Inc. Class A Common Stock's market cap, and Humana Inc pays a 0.84% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Humana Inc for 51 Days on average.

HNGEHUM
Market Cap
$8.48B$50.48B
Volume
879,7991,889,709
Sector
HealthHealth
52-Week High
$105.14$433.50
52-Week Low
$31.17$163.67
Typical Hold Time
0 Days51 Days
Enterprise Value
$8.10B$57.83B
Dividend Yield
—0.84%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hinge Health Inc. Class A Common Stock

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

Humana Inc

Humana (HUM) trades at $427.59, down 1.36% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is robust, reaching $129.66 billion in 2025, though net income margins have compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and strong institutional buying interest, while the company prepares for Q3 earnings on November 6.

The stock offers upside to the $469.89 consensus target but faces risks from margin pressure and regulatory scrutiny. Earnings beats in recent quarters support momentum, yet profitability trends and Medicare Advantage plan changes require monitoring for sustained growth.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HNGE
100% Buy0% Sell
Avg holding period · 0 Days
HUM

No sentiment data available yet.

Top news

Latest headlines on both assets

About Hinge Health Inc. Class A Common Stock

Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.

Read more on HNGE →

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM →